Dr. Bruce Bloom, March 28, 2013Bruce E. Bloom Informal Headshot

Two of our favorite organizations in the Repurposing Revolution are getting together to drive drug repurposing to patients. DART Therapeutic, a biotechnology firm started by a group of Duchenne muscular dystrophy (DMD ) voluntary health organizations, and Biovista, a partner of ours and the leader drug repurposing opportunity discovery entered into a research collaboration to identify and develop drug repositioning candidates for DMD using Biovista's Clinical Outcome Search Space (COSS)â„¢ technology. We've used the COSS technology to help us find some drug repositioning opportunities for leukemia, and are working with BioVista on several other diseases.  Read more in this recent press release.

In addition, one the DMD projects in our Rediscovery Researchâ„¢ portfolio has just gotten funding approval. This project, proposed by Dr. Subha Raman of Ohio State University, will complete a randomized, controlled clinical trial repurposing a drug typically reserved for advanced heart failure to delay heart disease in DMD patients.  

Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*


If the link above doesn't work, please email susan@cureswithinreach.org with your Full Name and Email Address to sign up!


Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602


All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.


Tuesday the 18th. Copyright 2018 Cures Within Reach.